Cargando…
Immunotherapy for glioblastoma: the promise of combination strategies
Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. In recent years, immunotherapy strategies have revolutionized the treatment of many cancers...
Autores principales: | Bausart, Mathilde, Préat, Véronique, Malfanti, Alessio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787896/ https://www.ncbi.nlm.nih.gov/pubmed/35078492 http://dx.doi.org/10.1186/s13046-022-02251-2 |
Ejemplares similares
-
Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model
por: Bausart, Mathilde, et al.
Publicado: (2022) -
Design of Bio-Responsive Hyaluronic Acid–Doxorubicin Conjugates for the Local Treatment of Glioblastoma
por: Malfanti, Alessio, et al.
Publicado: (2022) -
Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by α-tocopherol succinate micelles for the treatment of glioblastoma
por: Wang, Mingchao, et al.
Publicado: (2022) -
Mismatch between Bioluminescence Imaging (BLI) and MRI When Evaluating Glioblastoma Growth: Lessons from a Study Where BLI Suggested “Regression” while MRI Showed “Progression”
por: Bausart, Mathilde, et al.
Publicado: (2023) -
New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)